Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc (NASDAQ:BCAX), sold a total of 48,500 shares of common stock in multiple transactions on October 6 and 7. The timing is notable as the stock has shown remarkable strength, gaining over 93% in the past six months and about 9% in the last week alone. According to InvestingPro analysis, the stock is currently trading above its Fair Value, with technical indicators suggesting overbought conditions. The sales were executed at a weighted average price ranging from $18.0555 to $18.0591, netting Cohlhepp approximately $911,841.
On the same dates, Cohlhepp also exercised options to acquire 32,000 shares of Bicara Therapeutics common stock at a price of $3.7898, for a total value of $121,273.
These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, Cohlhepp directly owns 202,641 shares of Bicara Therapeutics Inc.
In other recent news, Bicara Therapeutics has been the focus of multiple analyst reports and developments. TD Cowen reiterated its Buy rating on Bicara Therapeutics, noting the $8 billion acquisition of Merus by Genmab as a positive sign for the field of EGFR bispecific antibodies, in which Bicara is active. Jones Trading also initiated coverage on Bicara with a Buy rating and set a price target of $22.00, highlighting promising clinical data for its bispecific antibody treatment for head and neck cancer. Meanwhile, H.C. Wainwright adjusted its price target for Bicara to $40.00 from $41.00, maintaining a Buy rating but citing increased long-term operating expenses. Piper Sandler began coverage with an Overweight rating and a $36.00 price target, pointing out a gap between market perception and expert opinions on Bicara’s ficera treatment. Additionally, the Rice Biotech Launch Pad has added Carolyn Ng from TPG Life Sciences to its advisory board, although this news is not directly related to Bicara, it reflects ongoing interest and activity in the biotech sector. These developments indicate continued interest and varied perspectives from analysts on Bicara Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.